Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group MA.31 -- A Randomized, Open-Label, Phase III Study of Taxane-Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer -- was closed to accrual on December 1, 2011.

Total accrual was 652 patients which is expected to be sufficient to provide the protocol sample size of 536 central lab-confirmed HER2/neu patients.

A total of 21 countries contributed to accrual.

Congratulations and thanks to all participating centres and patients.